Prostate Specific Antigen News and Research

RSS

UCL to co-lead Prostate Cancer UK's new £42m screening trial

UCL academics will co-lead Prostate Cancer UK's new £42m screening trial, which aims to find the best way to screen men for prostate cancer and double the number of lives saved.

2 May 2024

New urine-based test improves identification of high-grade prostate cancer

Researchers at the University of Michigan Rogel Cancer Center have developed a new urine-based test that addresses a major problem in prostate cancer: how to separate the slow-growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.

18 Apr 2024

Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels

For patients with locally advanced prostate cancer, combined treatment with chemotherapy and hormonal therapy offers extended control of prostate-specific antigen (PSA) levels, compared to hormonal therapy alone, reports a study in the April issue of The Journal of Urology, an Official Journal of the American Urological Association.

17 Apr 2024

Three-step prostate cancer screening method demonstrates reduced overdiagnosis

A large randomized trial conducted at Tampere University and the University of Helsinki shows that a new three-step prostate cancer screening method can find a considerable number of aggressive cancers.

10 Apr 2024

Educational video boosts prostate cancer screening intentions in men

As part of a comprehensive effort to improve cancer screenings among diverse communities, Penn Medicine's Abramson Cancer Center (ACC) Community Outreach and Engagement team developed a culturally sensitive educational video to address prostate cancer screening disparities.

10 Apr 2024

Blood test every five years could revolutionize prostate cancer screening

A simple blood test every five years is sufficient to screen low risk men for prostate cancer, new research has shown.

5 Apr 2024

Lancet Commission predicts sharp increase in global prostate cancer cases

Cases of prostate cancer are projected to double from 1.4 million per year in 2020 to 2.9 million per year by 2040, with low- and middle-income countries (LMICs) predicted to see the highest increases in cases, according to The Lancet Commission on prostate cancer which will be launched by a presentation at the European Association of Urology Congress.

4 Apr 2024

Combining MRI and blood tests to avoid unnecessary prostate biopsies

MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, new research suggests.

29 Mar 2024

Common prostate cancer test may leave black men at increased risk of overdiagnosis

A new study from experts at the University of Exeter has found that a widely used test for prostate cancer may leave black men at increased risk of overdiagnosis.

29 Feb 2024

What factors are associated with recent prostate-specific antigen screening in transgender women?

A new study reports on factors associated with prostate cancer screening among transgender women.

19 Feb 2024

Combination drug therapy beats solo treatment for aggressive prostate cancer relapse

Combining testosterone-blocking drugs in patients with prostate cancer relapse prevents the spread of cancer better than treatment with a single drug, a multi-institution, Phase 3 clinical trial led by UC San Francisco researchers has found.

23 Jan 2024

Team approach to prostate cancer: PCPs and urologists offer hope with active surveillance

This study considers the perspectives of primary care physicians (PCPs) and urologists on what facilitates and what creates barriers to active surveillance (AS) care for men with low-risk prostate cancer.

22 Jan 2024

New study challenges role of rectal exam in prostate cancer screening

A study by the Comprehensive Cancer Center Vienna of MedUni Vienna and Vienna General Hospital has taken a closer look at the effectiveness of common examination methods for the early detection of prostate cancer.

19 Jan 2024

Are there racial and ethnic disparities in the use of novel hormonal therapy agents in men with advanced prostate cancer?

Researchers assessed ethnic and racial differences in novel hormonal therapy (NHT) use among advanced prostate cancer (PCa) patients.

6 Dec 2023

Exploring the impact of soy isoflavones in prostate cancer therapy

The cellular mechanisms of soy isoflavones, genistein, daidzein, and equol.

23 Nov 2023

Multi-ancestry study reveals 187 new genetic risk factors for prostate cancer

In a comprehensive multi-ancestry GWAS meta-analysis, researchers identified 451 risk variants for prostate cancer, including 187 new variants, demonstrating the utility of such studies across diverse populations. This analysis not only increased understanding of genetic risk factors but also differentiated between aggressive and non-aggressive prostate cancer types, underscoring the potential of genetic risk scoring in guiding screening and early detection strategies.

12 Nov 2023

Docetaxel improves survival in men with high-grade prostate cancer and low PSA

Men with high-grade prostate cancer and low prostate-specific antigen (PSA) levels have a poor prognosis.

1 Nov 2023

Red grape polyphenol, resveratrol: a multifaceted therapeutic powerhouse under review

The therapeutic potential of resveratrol, a red grape polyphenol.

25 Oct 2023

Genomic testing rates soar for Black patients with prostate cancer after introduction of precision medicine navigators

The presence of a clinical navigator to act as a liaison between people with prostate cancer and the health care system greatly increases the likelihood that patients, especially Black patients, will receive advanced testing that can help predict the severity of their disease and guide treatment, a new study suggests.

3 Oct 2023

Study challenges the use of biochemical recurrence as prostate cancer predictor

A UCLA-led study found treatments that reduce the risk of being diagnosed with a cancer recurrence based on rising prostate-specific antigen (PSA) levels after radiotherapy, commonly referred to as biochemical recurrence, do not necessarily improve a patient's long-term overall survival.

28 Aug 2023